Associations of Metformin Use History With Delirium and Mortality in Patients With Type 2 Diabetes Mellitus: A Retrospective Cohort Study
Abstract
BACKGROUND: Higher body mass index (BMI) generally increases susceptibility to certain diseases. However, previous studies have shown that metformin, a medication for type 2 diabetes mellitus (T2DM), can improve various outcomes, including survival in obese patients. This indicates that the effectiveness of metformin on certain outcomes is more pronounced in those with a higher BMI. It remains unclear if the effects of metformin on delirium risk differ according to BMI.
METHODS: This study analyzed a subset of 506 T2DM subjects from the cohort used in our previous study. We compared delirium cases identified during hospitalization and survival curves among T2DM subjects with and without a history of metformin use, stratified by BMI. Furthermore, we investigated the influence of metformin use history and various other factors on cases of delirium identified during hospitalization and 3-year mortality among T2DM subjects in different BMI groups.
RESULTS: Metformin use history was associated with fewer cases of delirium (odds ratio = 0.422, 95% confidence interval [CI] = 0.217-0.820, P = 0.011) and lower 3-year mortality (hazard ratio = 0.564, 95% CI = 0.342-0.931, P = 0.025) among the BMI ≥30 group. On the other hand, the associations between metformin use history and fewer cases of delirium (odds ratio = 0.606, 95% CI = 0.320-1.150, P = 0.125) and lower 3-year mortality (hazard ratio = 0.754, 95% CI = 0.447-1.270, P = 0.288) among the BMI <30 group were relatively small and…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 506 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.